Introduction
In the myocardium, the coordinated contraction of cardiomyocytes is essential for the maintenance of a regular cardiac rhythm. Cardiomyocytes are coupled via gap junctions and in ventricular cardiomyocytes, connexin 43 (Cx43) is the predominant protein forming gap junctions or non-junctional hemichannels (Schulz et al., 2015) . Reductions in electrical cell coupling via decreased amounts of Cx43 or reduced Cx43 phosphorylation contribute to ischaemia-induced arrhythmogenesis (Beardslee et al., 2000; Lerner et al., 2000) . In order to maintain intercellular coupling, anti-arrhythmic peptides were developed (De Vuyst et al., 2011) . The application of the hexapeptide rotigaptide (formerly called ZP123) inhibits gap junction uncoupling by ischaemia (Xing et al., 2003; Kjolbye et al., 2007) , induces gap junctional communication via Cx43-formed channels (Clarke et al., 2006) , and prevents the ischaemia-induced dephosphorylation of myocardial Cx43 (Axelsen et al., 2006) . ZP1609, (2S, 4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid, (also known as GAP-134 or danegaptide) is a dipeptide analogue of rotigaptide. ZP1609 prolongs the time to conduction block in a mouse model of CaCl 2 -induced arrhythmias ) and reduces atrial fibrillation in dog hearts undergoing simultaneous atrioventricular pacing (Laurent et al., 2009) or in dogs with sterile pericarditis .
Gap junctions are not only important for arrhythmias but are also involved in myocardial damage by ischaemia/ reperfusion (I/R) injury since their uncoupling reduces infarct size (Rodriguez-Sinovas et al., 2004; Shintani-Ishida et al., 2009 ). Cx43-formed hemichannels, which are predominantly closed under physiological conditions, open during ischaemia (Saez and Leybaert, 2014) and the prevention of their opening protects against I/R injury (Shintani-Ishida et al., 2007; Wang et al., 2013) . Both rotigaptide and ZP1609 decrease myocardial infarct size in dog and pig hearts when administered before reperfusion (Hennan et al., 2006; Hennan et al., 2009; Skyschally et al., 2013; Pedersen et al., 2016) . In a model of renal I/R injury, however, ZP1609 did not improve renal function (Amdisen et al., 2016) .
Apart from being present at the plasma membrane, Cx43 is also found in subsarcolemmal mitochondria (SSM, located directly under the sarcolemma), whereas interfibrillar mitochondria (IFM), which are present between the myofibrils, lack Cx43 (Boengler et al., 2009; Sun et al., 2015) . SSM and IFM differ in their function, in that IFM consume more oxygen than SSM (Palmer et al., 1977) and take up more calcium until opening of the mitochondrial permeability transition pore (MPTP) occurs (Palmer et al., 1986) . Data derived from different experimental approaches support the existence of Cx43-formed channels within mitochondria (Miro-Casas et al., 2009; Boengler et al., 2013; Soetkamp et al., 2014) . Cx43 is involved in mitochondrial function in several aspects including respiration, potassium handling, ROS formation, MPTP opening, mitochondrial dynamics and mitophagy (Miro-Casas et al., 2009; Tyagi et al., 2010; Boengler et al., 2012; Boengler et al., 2013; Givvimani et al., 2014; Soetkamp et al., 2014; Srisakuldee et al., 2014) , parameters all contributing to myocardial I/R injury.
As the protection afforded by ZP1609 requires either predominantly open (antiarrhythmic properties) or closed (reperfusion injury) channels, it is important to investigate whether this compound directly targets Cx43. Possibly, ZP1609 might also act on a subset of mitochondria important for modulating the functional consequences of I/R injury in cardiomyocytes. To test this hypothesis, we assessed the effects of ZP1609 on mitochondrial function, especially on parameters known to be influenced by Cx43 and important for I/R injury in Cx43-containing SSM and Cx43-free IFM. In addition, the effects of ZP1609 on cardiomyocyte hypercontracture following I/R and biochemical pathways influenced by ZP1609 were analysed.
Methods

Animals
All animal care and experimental procedures in this study conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and were approved by the animal welfare office of the Justus-Liebig-University Giessen. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) . For the isolation of cardiomyocytes and studies of mitochondrial function 10-12 weeks old male C57Bl6J mice (25-30 g, Janvier, Le Genest-Saint-Isles, France) were used. These methods have been in use for several years (Schluter and Schreiber, 2005; Boengler et al., 2009) . Because of the well-established response of the mouse heart towards I/R injury, the importance of mitochondria in myocardial injury, the feasibility of characterising isolated cardiomyocytes and of studying various aspects of mitochondrial function, the mouse (heart) is appropriate for the present study. The mice (up to 5 per cage) were kept in dark/light cycles of 12 h each and had free access to standard chow and drinking water. Mice were anaesthetized with 5% isoflurane, killed by cervical dislocation, and subsequently hearts were removed.
Isolation of mitochondria
Subarcolemmal (SSM) and IFM were isolated from C57Bl6J mice as previously described (Boengler et al., 2009) . All steps were performed at 4°C. In short, hearts were washed in buffer A [100 mM KCl, 50 mM 3-[N-morpholino]-propanesulfonic acid (MOPS), 5 mM MgSO 4 , 1 mM ATP, 1 mM EGTA, pH 7.4] and weighed. Tissue was minced in 10 mL·g À1 buffer B (buffer A + 0.04% BSA) with scissors and was then disrupted with a Potter-Elvejhem tissue homogenizer. The homogenate was centrifuged for 10 min at 800 g. The supernatant containing the SSM was centrifuged for 10 min at 8000 g. The sedimented mitochondria were washed in buffer A and were resuspended in a small volume of buffer A. The sediment of the first centrifugation containing the IFM was resuspended in buffer B (10 mL·g À1 tissue). About 8 U·g À1 of the protease nagarse were added and incubated at 4°C for 1 min. After disruption with a Potter-Elvejhem tissue homogenizer and centrifugation for 10 min at 800 g the supernatant was centrifuged for 10 min at 8000 g to collect the IFM. The resulting mitochondria were washed by resuspension in buffer A; they were centrifuged at 8000 g for 10 min, and finally resuspended in buffer A. These mitochondrial preparations were used to study respiration, ATP production, ROS formation, MPTP opening and potassium uptake. Animals were not randomized, but the isolated mitochondria from one animal were always subjected to all treatment groups. The order in which the samples were analysed for mitochondrial function was randomized, and the experiments and the analysis of the data were conducted by two different persons. The analysis of mitochondrial function adheres to strict rules in terms of periods of time analysed and was identical for all treatment groups. To analyse the amount of Cx43 in SSM and IFM by Western Blot, mitochondria were further purified by layering them on top of a 30% Percoll solution in isolation buffer (in mM: sucrose 250; HEPES 10; EGTA 1; 0.5% BSA; pH 7.4) and subsequent ultracentrifugation at 35 000 g for 30 min at 4°C. The mitochondrial band was collected, washed twice in isolation buffer by centrifugation at 8000 g for 5 min, and the purified mitochondria were stored at À80°C. For reference see (Boengler et al., 2012) . Oxygen consumption was measured from untreated SSM and IFM, or after incubation for 30 min at 4°C in isolation buffer under control conditions or with either 10, 100 nM, 1 or 10 μM ZP1609.
Mitochondrial oxygen consumption
Mitochondrial ATP production
Mitochondrial ATP production was analysed from samples (50 μg) of SSM or IFM incubated under control conditions or after incubation for 30 min at 4°C with 1 or 10 μM ZP1609. After the incubation, mitochondria were diluted in 100 μL incubation buffer supplemented with 5 mM glutamate and 2.5 mM malate and 0.1 mM di-adenosine-pentaphosphate. About 100 μL of the ATP bioluminescent assay kit (1:5 diluted with incubation buffer, Sigma-Aldrich, Munich, Germany) was added and the bioluminescence was recorded for 1 min with a ZP1609 reduces mitochondrial ADP-stimulated respiration. ADPstimulated mitochondrial oxygen consumption (in % of controlincubated mitochondria) was measured in SSM and IFM using substrates for complexes 1 or 2 in the presence of 10, 100 nM, 1 or 10 μM ZP1609. * P < 0.05, significantly different from control.
Cary Eclipse spectrophotometer (Agilent Technologies, Santa Clara, CA) at room temperature to assess background values. ATP generation was initiated by the addition of 500 mM ADP and the bioluminescence was recorded for another 5 min. The mean value of the bioluminescence for 5 min after the addition of ADP was calculated, the background bioluminescence was subtracted, and the value of control SSM was set as 100%. This normalization was performed in order to eliminate variations in ATP production depending on the actual quality of the mitochondrial preparation. Three replicates were performed per group.
Calcium-induced MPTP opening
The calcium retention capacities of 100 μg·mL À1 SSM or IFM incubated under control conditions or with ZP1609 (1, 10 μM) were analysed in incubation buffer (glutamate/malate as substrates for complex 1, no EGTA) at 25°C. Calcium Green 5 N fluorescence (0.5 μM, Invitrogen, Carlsbad, CA) was used to detect extramitochondrial calcium with a Cary Eclipse spectrophotometer at excitation and emission wavelengths of 500 and 530 nm respectively. Approximately 5 μM CaCl 2 were added every third minute until a sudden increase in Calcium Green 5 N fluorescence occurred reflecting MPTP opening.
Mitochondrial ROS generation
Approximately 50 μg mitochondria (SSM or IFM) were incubated for 30 min (4°C) under control conditions, or with 1 or 10 μM ZP1609. Mitochondria were transferred to incubation buffer supplemented with 5 mM glutamate and 2.5 mM malate 2.5, 50 μM Amplex UltraRed (Invitrogen, Eugene, OR), and 0.1 U·mL À1 horseradish peroxidase. The fluorescence was measured continuously for 4 min with a Cary Eclipse spectrophotometer at the excitation/emission wavelengths of 565/581 nm respectively. As positive control, we used control mitochondria supplemented with 2 μM of the complex I inhibitor rotenone. Background fluorescence
Figure 3
Effects of ZP1609 on mitochondrial oxygen consumption. Mouse SSM and IFM were incubated under control conditions (con) or with 1 or 10 μM ZP1609. Basal and ADP-stimulated respiration were measured using substrates for complex 1 in SSM (A) and IFM (B), and using substrates for complex 2 in both SSM (C) and IFM (D), * P < 0.05 significantly different as indicated.
of the buffer without mitochondria was subtracted and the slope (fluorescence in arbitrary units/time) was calculated. The data on ROS formation were normalized as % of control in order to eliminate variations in ROS formation depending on the actual quality of the mitochondrial preparation.
Mitochondrial potassium influx
Freshly isolated SSM or IFM were incubated under control conditions, with 1 or 10 μM ZP1609 for 20 min at 4°C. Subsequently, mitochondria were loaded with 10 μM PBFI-AM [acetoxymethyl ester of PBFI (potassium-binding benzofuran isophthalate; Life Technologies, Carlsbad, CA)] diluted 2:1 with 20% pluronic F127 by additional incubation at 25°C for 10 min according to the protocol by Costa et al. (2006) . Three volumes of TEA (tetraethylammonium) buffer (in mM: TEA-Cl 120, HEPES 10, succinate 10, Na 2 HPO 4 5, EGTA 0.1, MgCl 2 0.5, rotenone 5 μM, oligomycin 0.67 μM, pH 7.2) were added, and the mitochondria were incubated for 2 min. Thereby, K + ions are replaced within the mitochondrial matrix. Subsequently, the mitochondria were washed twice in isolation buffer and the protein concentration was measured using the Dc protein assay (BioRad, Hercules, CA). A sample of 200 μg mitochondrial proteins (SSM or IFM) was incubated for 30 min at 4°C under control conditions or with 1 or 10 μM ZP1609 respectively. Mitochondria (100 μg·mL À1 ) were added to isolation buffer supplemented with 1 μg·mL À1 oligomycin (inhibits ATP synthase), 50 μM glibenclamide (blocks mitochondrial ATP-dependent potassium channels), and 1 μM cyclosporin A (CsA; inhibits opening of the MPTP). The uptake of potassium into the mitochondria was induced by adding 140 mM KCl. The PBFI fluorescence was measured in a Cary Eclipse Fluorescence Spectrophotometer at alternating excitation wavelengths of 340 (maximum potassium sensitivity of the probe) and 380 nm (isosbestic point of the probe), respectively, and an emission wavelength of 500 nm at 25°C. The maximal slope of the PBFI fluorescence after the KCl pulse -corresponding to approximately 0.03 min -was determined.
Western blot analysis SSM and IFM purified by Percoll gradient ultracentrifugation (n = 4) were lysed in 1X NP40 buffer (25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, pH 7.4) supplemented with 1X PhosStop and Complete inhibitors (Roche, Basel, Switzerland) as well as 1 μM neocuproine. Protein concentration was determined using the Lowry assay. Thirty μg proteins were electrophoretically separated on 10% Bis/Tris gels and proteins were transferred to nitrocellulose membranes.
Figure 4
ZP1609 decreases mitochondrial ATP production. Original traces show the bioluminescence indicating ATP production from mouse SSM (A) and IFM (B) incubated under control conditions (con) or with 1 or 10 μM ZP1609. Background bioluminescence was recorded for 2 min, then 500 μM ADP was added to stimulate ATP generation, and the bioluminescence was monitored for another 5 min. (C) Quantification of ATP generation from control and ZP1609-treated SSM and IFM. Control-incubated SSM or IFM were set as 100%, * P < 0.05, significantly different from control (con).
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After blocking, membranes were incubated with rabbit polyclonal anti-human/rat Cx43 antibodies (Sigma) or rabbit polyclonal anti-human manganese SOD antibodies (Merck Millipore, Darmstadt, Germany). After washing and incubation with the respective secondary antibodies, immunoreactive signals were detected by chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate, ThermoFisher) and quantified using ScionImage software. The data on the predominant localization of Cx43 in SSM are confirmatory and have been published previously ZP1609 does not affect mitochondrial ROS formation. ROS formation was measured using Amplex UltraRed fluorescence and the slope of controlincubated mitochondria was set as 100%. Incubation of both SSM and IFM with 1 and 10 μM ZP1609 had no effect on ROS formation, n = 8. (Boengler et al., 2009; Soetkamp et al., 2014; Sun et al., 2015) . As the general expression of Cx43 varies in every animal analysed, we set the content of Cx43 in SSM as 100% to compare with the amount of Cx43 in IFM. No statistical analysis was undertaken.
Isolation of cardiomyocytes
Mouse ventricular cardiomyocytes were isolated as described previously (Schluter and Schreiber, 2005) . Briefly, hearts were digested with collagenase in the Langendorff-mode, minced, and further digested by incubation with collagenase buffer. The resulting suspension was filtered, and the separation of cardiomyocytes from non-myocytes was achieved by centrifugation. Finally, physiological calcium concentrations were readjusted by step-wise increases of calcium to 1 mM concentration, and cardiomyocytes were attached on glass-cover slips. Animals were not randomized, treatment of isolated cardiomyocytes started simultaneously in all groups.
In vitro ischaemia and reperfusion experiments
Isolated cardiomyocytes on glass cover-slips were introduced into a perfusion chamber and superfused with a flow rate of 1.75 mL·min À1 . The buffers were transferred into the perfusion chamber through gas-tight steel capillaries. Isolated cardiomyocytes were incubated under normoxic conditions in a HEPES buffer pH 7.4 (in mM: 118 NaCl, 4.7 KCl, 1.2 KH 2 PO 4 , 0.8 MgSO 4 , 2.5 CaCl 2 , 5 glucose, 1.9 sodium pyruvate and 10 HEPES). To simulate ischaemia, the pH of the buffer was reduced to 6.4 at 37°C, 5 mM DL-cysteine was added, and pyruvate and glucose were omitted. The buffer was equilibrated with 100% N 2 before and during experiments. Following ischaemia, the cells were reoxygenated by perfusion of a normoxic, glucose-and pyruvate containing buffer (pH 7.4). ZP1609 was dissolved (1 or 10 μM) in the respective buffers, as indicated. The experimental groups were as follows:
1. 30 min normoxia 2. 30 min normoxia with 10 μM ZP1609 3. 15 min ischaemia and 30 min reperfusion 4. 15 min normoxia, 15 min ischaemia and 30 min reperfusion with 1 or 10 μM ZP1609 present during the whole experiment (1 μM ZP1609-pre, 10 μM ZP1609-pre) 5. 15 min ischaemia, 30 min reperfusion with 1 or 10 μM ZP1609 present during reperfusion only (1 μM ZP1609-rep, 10 μM ZP1609-rep)
Subsequently, cover-slips were transferred to a microscope and five randomly selected pictures were taken for each cover-slip. Ischaemia-tolerant cardiomyocytes were identified by their rod-shaped structure. Hypercontracture leading to round-shaped cells was quantified. The total number of cells counted per experiment was 3391 ± 1385. The experiments and the evaluation of cardiomyocyte hypercontracture were performed by two different researchers.
Signal transduction
Isolated cardiomyocytes were subjected to normoxia, I/R, 10 μM ZP1609-pre, and 10 μM ZP1609-rep. Cells were collected using a cell scraper and stored at À80°C. Phosphorylation of 43 proteins and amounts of two related total proteins were studied using the Human Proteome Profiler Array (R&D Systems, Minneapolis, MN) according to the instructions of the manufacturer. To provide the sample size of 300 μg protein, cardiomyocytes from four mice were pooled. Immunoreactive signals were detected using SuperSignal West Femto Chemiluminescent Substrate, ThermoFisher) and were quantified using Scion Image software. Pixel intensities were corrected for the mean value of the negative controls, no statistical analysis was undertaken.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data are presented as mean values ± SEM and group sizes are equal. Data transformation was not performed. Mitochondrial respiration rates, potassium uptake, and data on cardiomyocyte hypercontracture were analysed by one-way ANOVA. Data on calcium-induced MPTP opening data were compared by two-way ANOVA. Data on mitochondrial ATP production and ROS generation were compared by Rank Sum test. A P < 0.05 indicated a significant difference. The program SigmaStat 3.5 (Systat, Software GmbH, Erkrath, Germany) was used for statistical analysis.
Materials
ZP1609 ((2S, 4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid) was synthesized at Zealand Pharma A/S (Glostrup, Denmark) with a purity of 99.8% as determined by HPLC. Other compounds were supplied as follows: CsA, Sigma-Aldrich; glibenclamide, Sigma-Aldrich; oligomycin, Sigma-Aldrich.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
Results
Mitochondria
To demonstrate the localization of Cx43 within mitochondrial subpopulations, SSM and IFM were isolated from mouse ventricles and characterized by Western blot analysis (Figure 1 ). The majority of Cx43 is found in SSM, whereas IFM contained negligible amounts of the protein.
IFM consume more oxygen than SSM (Palmer et al., 1977) . In untreated mitochondria, ADP-stimulated respiration (in nmol O 2 ·min À1 ·mg protein À1 ) using substrates for respiratory complex 1 or complex 2 was higher in IFM (complex 1: 97.4 ± 9.7; complex 2: 175.5 ± 8.7, n = 15) than in SSM (complex 1: 67.7 ± 5.9; complex 2: 140.4 ± 7.5, n = 14, P < 0.05).
To analyse the effect of ZP1609 on mitochondrial respiration, SSM and IFM were incubated under control conditions with different concentrations of ZP1609 (10 nM to 10 μM). Subsequently, ADP-stimulated respiration was measured using substrates for complex 1 and complex 2 and expressed as % of the untreated control value. Mitochondrial oxygen consumption was not affected by 10 nM ZP1609, but concentration-dependently decreased in SSM and IFM when treated with 100 nM and 1 μM ZP1609. The inhibition of ADP-stimulated respiration was comparable between 1 and 10 μM ZP1609 (Figure 2) , and was more pronounced in mitochondria respiring on complex 1 than on complex 2 substrates. ZP1609 did not influence basal respiration in SSM or IFM using substrates for complex 1 and 2. The absolute values of basal and ADP-stimulated oxygen consumption (complex 1 and 2 substrates) in SSM and IFM incubated under control conditions or with 1 and 10 μM ZP1609 are shown in Figure 3 . Because 1 and 10 μM ZP1609 had the most pronounced effect on mitochondrial oxygen consumption, these concentrations were used for further experiments.
Figure 9
ZP1609 alters the phosphorylation or amounts of proteins in cardiomyocytes undergoing I/R. The phospho-kinase array detects the phosphorylation status of several protein kinases in extracts of cardiomyocytes under normoxic conditions (Nx), I/R without or with 10 μM ZP1609 when applied during I/R (10 μM ZP1609-pre) or at the onset of reperfusion (10 μM ZP1609-rep). The proteins with the most obvious differences between groups are indicated. For the analysis, cardiomyocytes from four mice were pooled.
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Mitochondrial ATP-production was measured in SSM and IFM without or with 1 and 10 μM ZP1609 in the presence of complex 1 substrates. In accordance to the effect of ZP1609 on respiration, both SSM and IFM demonstrated less ATP generation in mitochondria treated with 10 μM ZP1609 (Figure 4) . Calcium-induced MPTP opening was analysed in SSM and IFM, without or with ZP1609 ( Figure 5 ). MPTP opening was calculated as the amount of CaCl 2 added to the mitochondrial preparations until a sudden increase in Calcium Green fluorescence appeared ( Figure 5A) .
In SSM and in IFM, the incubation with 1 ( Figure 5B ) and 10 μM of ZP1609 ( Figure 5C ) did not alter the calcium concentration required to induce MPTP opening. As expected, in the presence of the MPTP inhibitor CsA SSM and IFM retained more calcium until MPTP opening occurred.
As enhanced amounts of ROS facilitate MPTP opening, ROS formation was measured in SSM and IFM treated with ZP1609. However, neither 1 nor 10 μM ZP1609 influenced ROS formation in SSM or IFM (Figure 6 ).
The influence of ZP1609 on mitochondrial potassium uptake was measured as the increase in PBFI fluorescence after the addition of KCl in SSM and IFM incubated under control conditions, with 1 or 10 μM ZP1609 respectively. The excitation at 380 nm (isosbestic point) resulted in a small increase in the PBFI fluorescence, which was similar between groups ( Figure 7) . However, the excitation at 340 nm demonstrated a rapid increase in the PBFI fluorescence until a plateau was reached. The maximal slope of the increase in the PBFI fluorescence over time was calculated. In SSM, the incubation with ZP1609 (either 1 or 10 μM) did not affect the potassium uptake. However, incubation of IFM with 10 μM ZP1609 significantly increased the maximal slope of the PBFI fluorescence, indicating enhanced mitochondrial potassium influx.
Cardiomyocytes
The effect of ZP1609 on hypercontracture was measured in freshly isolated mouse cardiomyocytes as the percentage of rod-shaped cardiomyocytes after incubation under normoxic conditions or following I/R. The percentage of rod-shaped cardiomyocytes following 30 min incubation under normoxic conditions was similar between control cells (77.3 ± 3.3%) and cells treated with 10 μM ZP1609 (79.1 ± 1.4%, n = 4 independent isolations).
Approximately 15 min ischaemia and 30 min reperfusion decreased the percentage of rod-shaped cardiomyocytes compared to normoxic conditions (Figure 8 ). The lower concentration of ZP1609 (1 μM ) had no effect on cardiomyocyte hypercontracture when present during 15 min normoxia followed by I/R, where 18.8 ± 8.7% (n = 3) of the cardiomyocytes had a rod-shaped phenotype or when added at the onset of reperfusion (23.4 ± 1.8%, n = 3) compared to I/R alone (19.9 ± 8.8%, n = 3). In contrast, the higher concentration of ZP1609 (10 μM) enhanced the number of rod-shaped cardiomyocytes, regardless of the time at which ZP1609 was applied (10 μM ZP1609-pre and 10 μM ZP1609-rep, Figure 8 ).
To study biochemical pathways influenced by ZP1609 (apart from Cx43), the phosphorylation of several protein kinases was measured in cardiomyocytes undergoing normoxia, I/R, 10 μM ZP1609-pre, and 10 μM ZP1609-rep (Figure 9 ). Whereas I/R increased the phosphorylation of PRAS40 (proline-rich Akt substrate of 40 kDa), compared with that under normoxic conditions, this phosphorylation was decreased in the groups treated with 10 μM ZP1609-pre or 10 μM ZP1609-rep. The phosphorylation of glycogen synthase kinase 3α/β (GSK-3 α/β) was reduced by I/R compared to normoxia but enhanced by ZP1609 (both 10 μM ZP1609-pre and 10 μM ZP1609-rep). In contrast to PRAS40 and GSK-3 α/β, which were similarly influenced by ZP1609, an increase in the level of HSP60 (heat shock protein 60) was found specifically in the group 10 μM ZP1609-rep. The exact pixel intensities are shown in Table S1 .
Discussion and conclusions
The compound ZP1609 was developed as a dipeptide with similar characteristics to those of rotigaptide, that is, enhancing gap junction conductance in order to decrease ischaemia-induced arrhythmias. Whereas the exact molecular target of ZP1609 is unclear up to now, the antiarrhythmic properties of the peptide suggested Cx43 was a potential target. As Cx43 is not only localized at the plasma membrane but also within cardiomyocyte SSM, we tested putative effects of ZP1609 on mitochondrial function. The fact that IFM did not contain Cx43 allowed these mitochondria to be used as an internal negative control.
Previous studies showed that mitochondria of conditional Cx43-knockout mice or mitochondria in which Cx43 was inhibited by the mimetic peptide Gap27 demonstrated decreased complex 1-mediated respiration, whereas complex 2-mediated respiration was unaffected. This effect was specific for Cx43-containing SSM (Boengler et al., 2012) . In the present study, ZP1609 decreased complex 1-mediated respiration and, to a lower extent, complex 2-mediated respiration in both SSM and IFM. In accordance with the data on mitochondrial oxygen consumption, ZP1609 inhibited ATP production in SSM and IFM. The magnitude of the reduction of ATP generation was comparable to that observed in a previous study (Boengler et al., 2012) . ATP production was more effectively inhibited by 10 μM ZP1609 compared to 1 μM ZP1609, whereas the decrease in complex 1-mediated respiration was similar between the two concentrations of ZP1609. This effect may be due to partial uncoupling of oxidative phosphorylation by the higher dose of ZP1609. The finding that ZP1609 affected the Cx43-lacking IFM suggests that ZP1609 may have other molecular targets, apart from Cx43, within these mitochondria.
The opening of the MPTP contributes to reperfusion injury in animal studies and in humans (Piot et al., 2008; Hausenloy et al., 2009) . Previous data showed that treatment of cardiac mitochondria with Gap27 reduced mitochondrial calcium retention capacity specifically in SSM (Srisakuldee et al., 2014) . In the present study, in all control groups, IFM took up more calcium until MPTP opening occurred, than the SSM -a phenomenon already described before (Palmer et al., 1986 ) -thereby indicating accurate separation of the two mitochondrial populations. The incubation of SSM and IFM with 1 or 10 μM ZP1609 did not change MPTP opening in both mitochondrial populations, again suggesting that ZP1609 acted through targets other than Cx43 -at least under basal conditions. Mitochondrial ROS are formed by the respiratory chain, but many other mitochondrial proteins contribute as well (Di Lisa et al., 2017) . As ZP1609 reduced mitochondrial respiration, ROS formation was measured in the presence or absence of ZP1609. Although ZP1609 reduced respiration it did not affect ROS formation. One explanation for this finding relates to the small amount of ROS produced by the respiratory chain; only 0.1% of the total oxygen consumption is used to form ROS (St-Pierre et al., 2002) and any minor change in the production rate might fall below the detection limit of the technique used for ROS determination. As ROS facilitate MPTP opening (Di Lisa et al., 2011) , the lack of any effect of ZP1609 on ROS formation is, however, in accordance with the lack of effect of ZP1609 on calcium-induced MPTP-opening.
Under physiological conditions, the open probability of mitochondrial potassium channels is suggested to be low, whereas an opening of these channels prior to sustained I/R confers cardioprotection (Schulz and Di Lisa, 2016) . Because pharmacological inhibition or genetic ablation of Cx43 reduces mitochondrial potassium influx (Miro-Casas et al., 2009; Boengler et al., 2013) , we assessed the effects of ZP1609 on mitochondrial potassium uptake. Whereas 1 μM ZP1609 did not alter potassium influx, the higher concentration (10 μM ZP1609) increased the entry of potassium into IFM, whereas it had no effect on SSM. Therefore, regarding all mitochondrial parameters analysed in the present study, potassium entry is the only factor where differences between SSM and IFM after treatment with ZP1609 were observed. The finding that the Cx43-free IFM are targeted by ZP1609 again strengthens the hypothesis that ZP1609 acts through factors other than Cx43.
Taken together, our data on the effect of ZP1609 on mitochondrial function demonstrated no SSM-dependent influence on respiration, ATP-production, ROS-generation, MPTP-opening, or potassium uptake. Therefore, it is likely that, within mitochondria under basal conditions, Cx43 is not a direct target of ZP1609.
Gap junctions are also involved in myocardial damage by I/R injury and their uncoupling reduces infarct size (Rodriguez-Sinovas et al., 2004; Shintani-Ishida et al., 2009 ). Cx43-formed hemichannels, which are predominantly closed under physiological conditions, open during ischaemia (Saez and Leybaert, 2014) and the prevention of their opening protects against I/R injury (Shintani-Ishida et al., 2007; Wang et al., 2013) . Therefore, gap junctional uncoupling or the prevention of hemichannel opening mediate protection, presumably by limiting the passage of a so-called 'death factor'. The passage of Na + -ions through gap junctions from hypercontracting cardiomyocytes with a damaged sarcolemma to adjacent cells and secondary entry of Ca 2+ -ions via reverse Na + /Ca 2+ -exchange contributes to the propagation of cell damage (Ruiz-Meana et al., 1999) . On the other hand, a down-regulation of Cx43 increases apoptosis (Yasui et al., 2000) , showing that preserved cell-cell interaction may increase the transfer of a 'survival factor'. Also, Cx43-formed hemichannels participate in the transduction of cytoprotective factors and this may involve the activation of protein kinases (Plotkin et al., 2002) . With reperfusion following periods of prolonged ischaemia, restoration of mitochondrial ATP synthesis in the presence of still elevated intracellular calcium concentrations caused hypercontracture of cardiomyocytes leading to cell death (Garcia-Dorado et al., 2012) . As ZP1609 reduced mitochondrial ATP production and presumably targets sarcolemmal (hemi)-channels, we assessed the influence of the drug on the hypercontracture of isolated cardiomyocytes following I/R and were able to demonstrate a reduced amount of hypercontracting cardiomyocytes when ZP1609 was applied prior to ischaemia or prior to reperfusion only. Blocking hypercontracture by 2,3-butanedione monoxime or maintaining low pH during the early phase of reperfusion not only attenuated hypercontracture of cardiomyocytes but ultimately reduced infarct size (Garcia-Dorado et al., 1992; Cohen et al., 2008) . Similarly, ZP1609 decreased myocardial infarction when administered at reperfusion in vivo Skyschally et al., 2013) .
In glioma cells, ZP1609 ) reduced dyeuptake via Cx43-formed hemichannels, thereby suggesting hemichannel closure by ZP1609. Because opening of Cx43-formed hemichannels in cardiomyocytes contributes to loss of ionic gradients, cellular volume overload and finally cell damage (Schulz et al., 2015) , inhibition of hemichannel opening is cardioprotective (Wang et al., 2013) . However, as opening of Cx43-formed hemichannels is supposed to predominantly occur during ischaemia, the similar magnitude of protection by ZP1609 when applied before ischaemia or at reperfusion cannot be explained by hemichannel blockade.
Although there is no evidence from the data obtained in the present study that ZP1609 acts on Cx43 in cardiomyocytes, the potential for a direct or indirect interaction of ZP1609 with Cx43 remains. Indirect interaction through modulation of kinase activity has already been demonstrated for the anti-arrhythmic peptide AAP10 which modulated the phosphorylation status of Cx43 (Jozwiak and Dhein, 2008) . Also, rotigaptide prevented Cx43 de-phosphorylation induced by ischaemia (Kjolbye et al., 2007) . Specifically, the ischaemia-induced de-phosphorylation of Cx43 at Ser 297 and Ser 368 -which are targeted by PKC -was reduced following treatment with rotigaptide (Axelsen et al., 2006) . A putative effect of ZP1609 on Cx43 phosphorylation would presumably be restricted to sarcolemmal Cx43, as this compound exerts no specific effects on Cx43-containing SSM. Within mitochondria, ZP1609 probably acts independently of Cx43. In order to identify target proteins of ZP1609 (other than Cx43), the influence of ZP1609 on different biochemical pathways was studied. The analysis of the phosphorylation status of several proteins revealed that the drug prevented the I/R-induced de-phosphorylation of GSK3 α/β. The dephosphorylation of the protein by I/R has already been described before and corresponds to its activation, whereas the phosphorylation of GSK3 inactivates the protein (Miura and Tanno, 2010) . Inhibition of GSK3 exerts cardioprotective effects via the inhibition of MPTP opening at reperfusion BJP K Boengler et al. ( Juhaszova et al., 2004) , which also prevents cardiomyocyte hypercontracture (Ruiz-Meana et al., 2007) . Whereas in the present study no effects of ZP1609 on MPTP opening under basal conditions were observed, such effects may still occur after I/R. I/R induced the phosphorylation of PRAS40 and ZP1609 prevented such phosphorylation. PRAS40 was originally identified as a substrate of Akt and is known to inhibit the mTOR complex 1 (mTORC1) (Sancak et al., 2007) . An increase in the phosphorylation of PRAS40 is known to prevent the inhibition of mTORC1, and the inhibition of mTORC1 with PRAS40 decreases tissue damage after myocardial infarction (Volkers et al., 2013) . Therefore, the decreased phosphorylation of PRAS40 by ZP1609 may exert protection via decreased activity of mTORC1.
Whereas the effects of ZP1609 on the phosphorylation of GSK3 α/β or PRAS40 were not dependent on the time when ZP1609 was administered, differences occurred in the levels of HSP60, which was specifically increased by ZP1609-rep and not by ZP1609-pre. Together with HSP10, HSP60 acts as a mitochondrial chaperone and both factors are important for the folding of mitochondrial proteins. The overexpression of HSP60 in cardiomyocytes protects against I/R injury by maintaining mitochondrial integrity (Lin et al., 2001 ) and ZP1609 may contribute to the activation of such cardioprotective program. Taken together, the analysis of biochemical pathways influenced by ZP1609 results in the identification of putative target proteins, which may be involved in the protection of cardiomyocytes from I/R injury and which may function independently of Cx43.
ZP1609 is known to exert pharmacological effects in animal models of ventricular and atrial arrhythmias and its oral bioavailability presents the possibility for the prevention of cardiac arrhythmias in man. In addition, ZP1609 protects against myocardial I/R injury in animals. However, although published data suggest that ZP1609 acts on gap junctions via the modulation of Cx43, the present study indicates that ZP1609 can act independently of a direct interference with Cx43, at least at the level of mitochondria. In addition, new putative targets of ZP1609 were identified in the present study. This putative interference of ZP1609 with other factors has to be taken into account, when ZP1609 is further tested in clinical trials, and the identification of the exact protein(s) targeted by ZP1609 requires further studies.
Taken together, our data show that ZP1609 might exert cardioprotection by reducing the proportion of hypercontracting cardiomyocytes following I/R. It is possible that this protection is achieved through a reduction in mitochondrial respiration and ATP production rate. However, the protective effect of ZP1609 was independent of mitochondrial Cx43, as no difference in mitochondrial function was observed between Cx43-containing SSM and Cx43-free IFM.
